FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to sexual pathology, and can be used for therapy of erectile dysfunction in men. That is ensured by the sublingual introduction of a type 5 phosphodiesterase inhibitor - sildenafil citrate in dosage 12.5 mg 15 minutes prior to an expected coitus.
EFFECT: approach provides a fast, well-timed and optimal therapeutic effect with no by-effects due to lowering dose of the preparation twice as compared with an average therapeutic dose, as well as cost reduction and usability of the approach.
1 ex
